featured
Vedolizumab and Anti-TNFα Outcomes in Biologic-Naïve Patients With IBD
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Crohn's & Colitis
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Vedolizumab and Anti-Tumour Necrosis Factor α Real-World Outcomes in Biologic-Naïve Inflammatory Bowel Disease Patients: Results from the EVOLVE Study
J Crohns Colitis 2021 Oct 07;15(10)1694-1706, B Bressler, A Yarur, MS Silverberg, M Bassel, E Bellaguarda, C Fourment, A Gatopoulou, P Karatzas, U Kopylov, G Michalopoulos, S Michopoulos, U Navaneethan, DT Rubin, J Siffledeen, A Singh, K Soufleris, D Stein, D Demuth, GJ MantzarisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.